The FDA released its Biosimilar Action Plan (BAP), aimed at streamlining the approval and market entry of biosimilars.
“[The] FDA is taking new steps to promote the development of, and competition from, safe and effective biosimilars drugs. These lower cost alternatives can promote access to high-quality, necessary medicines,” tweeted FDA Commissioner Scott Gottlieb, MD, in promotion of the new plan.